JP2022541152A5 - - Google Patents

Info

Publication number
JP2022541152A5
JP2022541152A5 JP2022501111A JP2022501111A JP2022541152A5 JP 2022541152 A5 JP2022541152 A5 JP 2022541152A5 JP 2022501111 A JP2022501111 A JP 2022501111A JP 2022501111 A JP2022501111 A JP 2022501111A JP 2022541152 A5 JP2022541152 A5 JP 2022541152A5
Authority
JP
Japan
Prior art keywords
copper
composition
agent
approximately
ophthalmic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022501111A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022541152A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/041837 external-priority patent/WO2021007578A1/en
Publication of JP2022541152A publication Critical patent/JP2022541152A/ja
Publication of JP2022541152A5 publication Critical patent/JP2022541152A5/ja
Pending legal-status Critical Current

Links

JP2022501111A 2019-07-11 2020-07-13 多形態眼球製剤および治療法 Pending JP2022541152A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962873121P 2019-07-11 2019-07-11
US62/873,121 2019-07-11
PCT/US2020/041837 WO2021007578A1 (en) 2019-07-11 2020-07-13 Multi-agent ocular formulations and treatment methods

Publications (2)

Publication Number Publication Date
JP2022541152A JP2022541152A (ja) 2022-09-22
JP2022541152A5 true JP2022541152A5 (https=) 2023-07-21

Family

ID=74115334

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022501111A Pending JP2022541152A (ja) 2019-07-11 2020-07-13 多形態眼球製剤および治療法

Country Status (8)

Country Link
US (1) US20220288114A1 (https=)
EP (1) EP3996644A4 (https=)
JP (1) JP2022541152A (https=)
KR (1) KR20220125210A (https=)
CN (1) CN114364355A (https=)
AU (2) AU2020311441B2 (https=)
CA (1) CA3146848A1 (https=)
WO (1) WO2021007578A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019205774B2 (en) * 2018-01-05 2025-01-02 University Of Utah Research Foundation Treatment of myopic progression
TW202245810A (zh) * 2021-02-01 2022-12-01 美商艾維娜傳送系統公司 散光之治療
CN114225016B (zh) * 2021-12-02 2024-07-09 北京大学第一医院 一种用于抑制近视及圆锥角膜进展的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04502012A (ja) * 1989-09-27 1992-04-09 モスコフスキ ナウチノ―イススレドバテルスキ インスティテュト グラツィニフ ボレツネイ イメニ ゲルムゴルツァ 進行性近視の治療用組成物
AU7488898A (en) * 1997-05-16 1998-12-08 Corrective Vision, Inc. Improved contact lens
EP1397132A4 (en) * 2001-05-25 2006-12-13 Valley Forge Pharmaceuticals I OPHTHALMIC PIRENZEPINE GEL
US20060134226A1 (en) * 2004-11-16 2006-06-22 Todd Leonard Compositions useful to treat ocular neovascular diseases and macular degeneration
WO2012161655A1 (en) * 2011-05-23 2012-11-29 Singapore Health Services Pte Ltd Composition and/or method for reducing and/or preventing myopia progression comprising atropine
US9421199B2 (en) * 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US10010502B2 (en) * 2015-05-19 2018-07-03 Amorphex Therapeutics Llc Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation
EP3426262B1 (en) * 2016-03-08 2023-08-23 University of Utah Research Foundation Cross-linking agents and associated methods
US20200345542A1 (en) * 2017-11-21 2020-11-05 Sydnexis, Inc. Ophthalmic composition and delivery device thereof
AU2019205774B2 (en) * 2018-01-05 2025-01-02 University Of Utah Research Foundation Treatment of myopic progression

Similar Documents

Publication Publication Date Title
JP2021509902A5 (https=)
JP2022541152A5 (https=)
JP2019511493A5 (https=)
ES2708451T3 (es) Soluciones de bimatoprost y timolol sin conservantes
WO2014018856A1 (en) Compositions and treatment for eye diseases and disorders
WO2017115238A1 (en) Compositions for the treatment of presbyopia
EP2598119A2 (en) Preservative free brimonidine and timolol solutions
EP2588096A1 (en) Composition for prevention and treatment of contact lens papillary conjunctivitis and allergic eye disease
JP2018528169A (ja) 眼科用薬物の定量的な眼窩周囲への適用
EP1187611B1 (en) Ophthalmic histamine compositions and uses thereof
JP2015523986A (ja) ラキニモドを使用する眼炎症性疾患の治療
Bagnis et al. Antiglaucoma drugs: The role of preservative-free formulations
CN102018656A (zh) 含有效成分拉坦前列素的眼用凝胶剂及其制备方法
TWI805705B (zh) 選擇性syk抑制劑之使用方法及醫藥組合物
CN103202833A (zh) 一种奥洛他定或其盐的药用组合物及其制备方法
WO2025049378A1 (en) Netarsudil ophthalmological formulations with less toxicity
WO2024211322A2 (en) Ripasudil based ophthalmic treatments
AU2024298631A1 (en) Ocular surface topical administration of roflumilast for treatment of anterior and retinal-vitreous chamber ocular diseases
SMIT Anecortave Acetate for Steroid-Induced OHT
SA06270472B1 (ar) طريقة لمعالجة النوعين الاولي والثانوي للغلوكوما
HK1210968B (en) Compositions and treatment for eye diseases and disorders